What Percentage of Macular Degeneration Patients Go Blind?

Most people diagnosed with age-related macular degeneration (AMD) never go blind. Even among those who develop the most severe forms, total blindness, meaning the complete absence of light perception, is rare. AMD attacks central vision while leaving peripheral vision largely intact, so the typical outcome is a blurred or missing spot in the middle of your visual field rather than darkness. That said, AMD remains the leading cause of legal blindness in people over 65 in industrialized nations, and the percentage who reach that threshold depends heavily on which type of AMD you have, whether you receive treatment, and how early it is caught.

Legal Blindness Versus Total Blindness

When researchers and eye doctors talk about “going blind” from AMD, they almost always mean legal blindness, not the complete loss of sight. Legal blindness is defined as best-corrected visual acuity of 20/200 or worse in the better-seeing eye, which roughly corresponds to 35 or fewer letters on a standard eye chart.¹ At that level, you can still perceive light, shapes, and movement. You might recognize that someone is standing in front of you but not be able to read their expression. You can navigate a familiar room but cannot read standard print or drive. AMD almost never erases vision entirely because it damages the macula, the small area at the center of the retina responsible for sharp detail, while the surrounding retina continues to function.

This distinction matters because the fear many patients carry, that they will one day live in complete darkness, does not match what AMD actually does. The disease is serious and life-altering, but even in advanced stages, most people retain enough peripheral vision to move through their environment. The challenge is everything that requires fine central vision: reading, recognizing faces, watching television, and driving.

Dry AMD Versus Wet AMD and Their Very Different Risks

AMD comes in two forms, and the difference between them is enormous when it comes to severe vision loss. Dry AMD accounts for roughly 85 to 90 percent of all cases. It progresses slowly, sometimes over years or decades, as cells in the macula gradually thin and waste away. Most people with early or intermediate dry AMD never lose enough vision to meet the threshold for legal blindness, though reading and low-light tasks can become frustrating.

Wet AMD is less common but far more dangerous. It develops when abnormal blood vessels grow beneath the retina and leak fluid or blood, rapidly damaging the macula. Despite being the minority form, wet AMD is responsible for about 90 percent of cases where AMD leads to legal blindness.² Data from the Framingham Eye Study found that roughly 80 percent of eyes legally blind from AMD had the wet form, and a large case-control study put that figure at 90 percent, even though wet AMD is a relatively infrequent complication of the broader disease.²

The advanced stage of dry AMD, called geographic atrophy, can also cause significant central vision loss as patches of retinal cells die off completely. Geographic atrophy progresses more slowly than untreated wet AMD, but over years it can expand to cover the center of the macula and substantially impair vision. Until recently, there was no approved treatment for it.

How Anti-VEGF Injections Changed the Numbers

The introduction of anti-VEGF injections beginning in the mid-2000s transformed outcomes for wet AMD and cut the rate of legal blindness dramatically. These drugs block the growth factor that drives abnormal blood vessel formation beneath the retina. Before they existed, most people diagnosed with wet AMD faced a steep decline in central vision over months to a few years.

Population-level data from several countries tells a consistent story. In Denmark, the rate of legal blindness from AMD in people aged 50 and older dropped from about 52 cases per 100,000 per year in 2000 to roughly 26 per 100,000 in 2010, a reduction of 50 percent, with most of the decline occurring after anti-VEGF therapy became widely available.³ In Scotland, the rate dropped about 47 percent after ranibizumab was introduced. In Israel, a similar 51 percent decline was recorded over a decade. South Korea saw blindness incidence fall from about 44 per 100,000 person-years to around 16 per 100,000 between 2002 and 2013.⁴ A systematic review confirmed that anti-VEGF use in clinical practice was consistently associated with large reductions in AMD-related blindness.⁵

These numbers are encouraging, but they come with a caveat. Anti-VEGF therapy requires ongoing injections into the eye, often monthly or every other month, sometimes for years. Studies show that the prevalence of blindness from wet AMD continues to decline as long as treatment is maintained.⁶ When patients stop treatment or cannot access it consistently, vision often deteriorates. The treatment burden is real: frequent clinic visits, the discomfort of injections, and the cost all contribute to undertreatment in real-world practice.

What About the Other Eye?

If you develop wet AMD in one eye, the question of whether the other eye will follow is unavoidable. The evidence suggests it is a genuine risk. One long-term study found that about 42 percent of fellow eyes converted to wet AMD over 15 years of follow-up, with nearly half of those conversions happening within the first two years.⁷ A separate analysis using deep learning-based predictions found a similar overall conversion rate of just over 40 percent during more than six years of follow-up.⁸

This is why monitoring the second eye matters so much. When both eyes are affected and treatment is delayed or ineffective, the risk of meeting the legal blindness threshold rises considerably because you no longer have one good eye compensating. In another clinical series, the average time from starting treatment in the first eye to needing treatment in the second was about 12 months.⁹

Risk Factors That Push the Odds in One Direction

Smoking is the single most modifiable risk factor. A review of the evidence found that current smokers face a two- to three-fold increased risk of AMD compared to people who have never smoked, and the relationship shows a dose-response pattern: the more you smoke, the higher the risk.¹⁰ There is also evidence that quitting reduces the risk over time, which makes smoking one of the few AMD risk factors you can actually do something about.

Genetics plays a substantial role. Variants in genes known as CFH and ARMS2 are strongly associated with both developing AMD and progressing to its advanced forms. The more risk alleles you carry, the higher the incidence of early and late AMD.¹¹ Interestingly, these genetic variants may also influence how well standard nutritional supplements work. Research found that the AREDS supplement formulation modified the risk of progressing to wet AMD differently depending on a person’s genotype, with some genetic profiles appearing to benefit less or even see increased progression.¹² This is an area of active investigation and not yet standard clinical practice, but it hints at a future where supplement recommendations might be tailored to your DNA.

Racial and Ethnic Differences in Risk

AMD risk is not evenly distributed across racial and ethnic groups. In the Multi-Ethnic Study of Atherosclerosis, the eight-year incidence of late AMD was highest among White participants at about 4.1 percent, intermediate in Chinese and Hispanic participants, and lowest in Black participants at 0.4 percent.¹³ A separate managed-care analysis confirmed that Black adults had a substantially lower hazard of both dry and wet AMD relative to White adults, and the gap widened with age. At age 80, Black adults had about half the risk of wet AMD compared to White adults.¹⁴

These differences likely reflect a combination of genetic factors, pigmentation differences in the retinal pigment epithelium, and potentially unaccounted lifestyle or environmental factors. They do not mean that AMD is exclusively a disease of White populations; it occurs in all groups, just at different rates. And because awareness and screening are often lower in populations perceived to be at lower risk, delayed diagnosis can be a concern.

Do AREDS Supplements Actually Prevent Blindness?

You have probably heard about “eye vitamins” marketed for macular degeneration. These are based on the Age-Related Eye Disease Studies, large trials that tested specific combinations of vitamins and minerals in people who already had intermediate or advanced AMD in one eye. The original AREDS formulation (vitamins C and E, zinc, copper, and beta-carotene) reduced the risk of progressing to advanced AMD over several years. The follow-up trial, AREDS2, tested whether adding lutein, zeaxanthin, and omega-3 fatty acids would improve on that.

In the primary analysis of AREDS2, lutein plus zeaxanthin did not significantly reduce progression to advanced AMD compared to placebo over the initial study period.¹⁵ However, a longer-term follow-up at 10 years showed a modest but statistically significant benefit: those assigned to lutein and zeaxanthin had about a 9 percent lower risk of progression to late AMD.¹⁶ And when lutein/zeaxanthin was directly compared to beta-carotene as a substitute, lutein/zeaxanthin performed better, with a 15 percent lower risk of progression.¹⁶ Since beta-carotene also raises lung cancer risk in smokers, the current recommendation is lutein/zeaxanthin instead.

The supplements are not a cure and do not reverse damage that has already occurred. They are most relevant for people with intermediate AMD or advanced AMD in one eye who are trying to slow progression. If you have early AMD with no drusen or only a few small ones, the evidence for supplementation is weaker.

New Treatments for Geographic Atrophy

For decades, people with the advanced dry form of AMD, geographic atrophy, had no approved treatment. That changed in 2023 with the approval of pegcetacoplan (Syfovre), a complement inhibitor given by injection. Clinical trials showed that it slowed the growth rate of atrophic lesions compared to placebo, with a reduction of about 22 to 30 percent in lesion growth at 18 to 24 months depending on dosing frequency.¹⁷ A second complement inhibitor, avacincaptad pegol (Izervay), was also approved for the same indication.

These drugs slow atrophy expansion but do not restore lost cells or recover vision that has already been lost. Whether slowing geographic atrophy growth translates into meaningfully preserved reading ability or delayed legal blindness over the long term is still being studied. They represent genuine progress for a form of the disease that was previously untreatable, even if the effect size so far is modest.

Living with Vision Loss from AMD

For people who do experience significant central vision loss, low-vision rehabilitation can make a real difference in daily functioning. The key technique is eccentric viewing training, which teaches you to use a part of the retina adjacent to the damaged macula as a new fixation point. A study of this approach found that while visual acuity on the eye chart did not improve significantly, reading speed roughly doubled, going from about 26 letters per minute to 54 letters per minute after two weeks of training.¹⁸ A meta-analysis confirmed that eccentric viewing training produced the largest improvements in reading speed among the various low-vision rehabilitation strategies studied.¹⁹

Combined rehabilitation programs that pair eccentric viewing exercises with magnifying devices and prism-based image relocation have shown broader benefits, including improved contrast sensitivity, faster reading, and better face recognition.²⁰ These interventions do not restore normal sight, but they can preserve independence in tasks that matter most to patients.

Depression, Anxiety, and the Emotional Weight of AMD

The psychological burden of AMD deserves attention because it often goes unaddressed. Depression rates among people with AMD are substantially higher than in the general older population and comparable to rates seen in other chronic, disabling conditions.²¹ Both anxiety and depression are highly prevalent in patients with advanced AMD, driven by functional losses like the inability to read, drive, or recognize faces.²²

This matters practically because untreated depression can worsen functional outcomes. People who are depressed are less likely to keep up with injection schedules, attend rehabilitation sessions, or use assistive devices. If you or someone you care for has AMD and seems to be withdrawing from activities or expressing hopelessness, that is worth bringing up with a doctor, not just an eye doctor.

Charles Bonnet Syndrome and Visual Hallucinations

One of the more unsettling things that can happen with AMD-related vision loss is Charles Bonnet syndrome, in which people with damaged vision experience vivid visual hallucinations, patterns, faces, landscapes, or other images that they know are not real. A meta-analysis across more than 4,300 AMD patients found an overall prevalence of about 16 percent.²³ The rate was lower, around 7 percent, among patients seen routinely in clinic, and considerably higher, around 32 percent, among people attending visual rehabilitation centers, likely reflecting more severe vision loss in that group.

Among those who experience it, the majority describe the hallucinations as neither pleasant nor unpleasant.²⁴ The syndrome is not a sign of dementia or psychiatric illness; it is the brain filling in the gap where visual input has been lost. But many patients never mention it to their doctors because they fear being thought of as mentally unwell. Simply knowing that it is a recognized and common phenomenon can relieve a significant amount of distress.

The Financial Cost of Advanced AMD

Beyond the medical and emotional dimensions, advanced AMD carries serious financial consequences. A study of societal costs associated with wet AMD in the United States found that the mean annual cost for affected patients was roughly $40,000, compared to about $6,000 for a control group without AMD. For people with the most severe vision loss, in the range of 20/800 to no light perception, annual costs averaged about $83,000.²⁵ The surprise in these numbers is where the money goes. Direct medical costs, including injections and office visits, made up less than 18 percent of total costs. Caregiving, home help, and other nonmedical support accounted for about two-thirds of the total burden.²⁵

Additional cost categories that are often overlooked include assistive technology, fall-related injuries (a significant concern when central vision is compromised), transportation to frequent eye appointments, and nutritional supplements.²⁶ These costs tend to escalate as vision worsens, which is one reason early detection and consistent treatment have economic value well beyond the clinical benefits.

Home Monitoring and the Future of Early Detection

One promising development is the use of home-based optical coherence tomography (OCT) devices that let patients scan their own retinas between clinic visits. A prospective trial of a home OCT system in patients with wet AMD found that participants scanned their eyes an average of six times per week, and over 91 percent of those scans were usable for automated fluid analysis. During the home monitoring period, the interval between injections nearly doubled, from about eight weeks to about 15 weeks, without any significant loss of visual acuity.²⁷ If confirmed in larger trials, this approach could reduce the treatment burden that causes so many patients to fall behind on their injection schedules while still catching disease activity early enough to prevent vision loss.